{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=25&sponsor=Boehringer+Ingelheim",
    "query": {
      "sponsor": "Boehringer Ingelheim",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 673,
    "total_pages": 68,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=26&sponsor=Boehringer+Ingelheim&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=24&sponsor=Boehringer+Ingelheim&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T16:02:27.587Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02393755",
      "title": "Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colon Adenocarcinoma",
        "Rectal Adenocarcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2015-05-08",
      "completion_date": "2021-05-18",
      "has_results": true,
      "last_update_posted_date": "2021-07-08",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Buffalo, New York",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02393755"
    },
    {
      "nct_id": "NCT06272058",
      "title": "A Study to Test How Avenciguat (BI 685509) is Taken up in the Body of People With and Without Liver Problems",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "Avenciguat (BI 685509)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 4,
      "start_date": "2024-05-03",
      "completion_date": "2024-07-02",
      "has_results": false,
      "last_update_posted_date": "2025-07-17",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06272058"
    },
    {
      "nct_id": "NCT03822832",
      "title": "A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dermatitis, Atopic"
      ],
      "interventions": [
        {
          "name": "BI 655130",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 51,
      "start_date": "2019-02-12",
      "completion_date": "2020-07-22",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Miami, Florida + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822832"
    },
    {
      "nct_id": "NCT02175238",
      "title": "Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "BI 691751 fasted",
          "type": "DRUG"
        },
        {
          "name": "BI 691751 after high fat breakfast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2014-07",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02175238"
    },
    {
      "nct_id": "NCT00720499",
      "title": "Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "BI 1744 CL plus tiotropium bromide",
          "type": "DRUG"
        },
        {
          "name": "Respimat® Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 141,
      "start_date": "2008-07",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2015-08-17",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 5,
      "location_summary": "Clearwater, Florida • Tampa, Florida • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Killeen",
          "state": "Texas"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00720499"
    },
    {
      "nct_id": "NCT06558344",
      "title": "A Study to Test Different Doses of BI 1569912 in People With Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "5 mg BI 1569912",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BI 1569912",
          "type": "DRUG"
        },
        {
          "name": "10 mg BI 1569912",
          "type": "DRUG"
        },
        {
          "name": "20 mg of BI 1569912",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 225,
      "start_date": "2024-10-01",
      "completion_date": "2025-05-12",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 35,
      "location_summary": "Bellflower, California • Long Beach, California • Oceanside, California + 31 more",
      "locations": [
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06558344"
    },
    {
      "nct_id": "NCT01897532",
      "title": "Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6991,
      "start_date": "2013-07-10",
      "completion_date": "2018-01-18",
      "has_results": true,
      "last_update_posted_date": "2019-04-04",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 197,
      "location_summary": "Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Tuscumbia",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01897532"
    },
    {
      "nct_id": "NCT02197416",
      "title": "Safety of Dabigatran Etexilate in Blood Clot Prevention in Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Venous Thromboembolism",
        "Secondary Prevention"
      ],
      "interventions": [
        {
          "name": "dabigatran etexilate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 214,
      "start_date": "2014-09-29",
      "completion_date": "2019-11-19",
      "has_results": true,
      "last_update_posted_date": "2020-06-04",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 9,
      "location_summary": "Sacramento, California • Miami, Florida • Tampa, Florida + 6 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02197416"
    },
    {
      "nct_id": "NCT00106821",
      "title": "Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Tiotropium Bromide Inhalation Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 166,
      "start_date": "2004-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Sepulveda, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sepulveda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00106821"
    },
    {
      "nct_id": "NCT01892384",
      "title": "Safety and Tolerability of BI 409306 in Patients With Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "BI 409306",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2013-06-28",
      "completion_date": "2013-12-05",
      "has_results": true,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-10-16T16:02:27.587Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892384"
    }
  ]
}